RAPT Therapeutics, Inc. (0RA.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Brian Russell Wong M.D., Ph.D. | CEO, President & Director | 927.04k | -- | 1972 |
| Mr. Rodney K. B. Young | CFO, Principal Accounting Officer & Secretary | 630.81k | -- | 1963 |
| Dr. William Ho M.D., Ph.D. | Chief Medical Officer | 625.15k | -- | 1966 |
| Steve Young Ph.D. | Vice President of Technology | -- | -- | -- |
| Dr. Dirk G. Brockstedt Ph.D. | Chief Scientific Officer | 431.92k | -- | 1969 |
| Mr. Michael Listgarten | General Counsel | -- | -- | -- |
| Ms. Gwen R. Carscadden | Chief Human Resources Officer | -- | -- | 1961 |
| Dr. Paul Kassner Ph.D. | Senior Vice President of Biology | -- | -- | 1967 |
| Ms. Jennifer Nicholson | Senior Vice President of Regulatory Affairs & Quality Assurance | -- | -- | -- |
| Dr. Nipun Davar MBA, Ph.D. | Senior Vice President of Technical Operations | -- | -- | 1968 |
RAPT Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 68
Description
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Corporate Governance
Upcoming Events
May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
RAPT Therapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available